BioXcel Therapeutics, Inc. (BTAIQ)
OTCMKTS · Delayed Price · Currency is USD
0.042919
-0.030981 (-41.92%)
At close: Sep 8, 2026
BioXcel Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Operating Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -70.86 | -69.9 | -59.6 | -179.05 | -165.76 | -106.93 |
Depreciation & Amortization | 0.23 | 0.3 | 0.31 | 0.32 | 0.33 | 0.3 |
Other Amortization | 2.19 | 1.65 | 0.47 | 1.37 | 0.86 | - |
Loss (Gain) From Sale of Assets | - | - | - | 0 | 0.02 | 0.05 |
Stock-Based Compensation | 1.82 | 2.77 | 6.16 | 18.61 | 17.34 | 19.46 |
Other Operating Activities | 7.47 | 3.51 | -20.18 | -0.44 | 0.39 | - |
Change in Accounts Receivable | -0.07 | -0.1 | -0.06 | 0.18 | -0.25 | - |
Change in Inventory | 0.02 | -0.04 | 1.31 | -0.01 | -1.99 | - |
Change in Accounts Payable | 10.98 | 6.97 | -4.33 | -3.22 | 13.03 | 4.85 |
Change in Other Net Operating Assets | -2.69 | -2.77 | 3.9 | 7.23 | 0.68 | 0.13 |
Operating Cash Flow | -50.9 | -57.62 | -72.03 | -155.01 | -135.34 | -82.15 |
Operating Cash Flow Growth | - | - | - | - | - | - |
Investing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Capital Expenditures | - | - | - | -0.02 | -0.14 | -0.45 |
Investing Cash Flow | - | - | - | -0.02 | -0.14 | -0.45 |
Financing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Long-Term Debt Issued | - | - | - | - | 98.6 | - |
Total Debt Issued | - | - | - | - | 98.6 | - |
Long-Term Debt Repaid | - | - | -2.5 | - | - | - |
Total Debt Repaid | -8.41 | - | -2.5 | - | - | - |
Net Debt Issued (Repaid) | -8.41 | - | -2.5 | - | 98.6 | - |
Issuance of Common Stock | 55.6 | 58.14 | 39.69 | 27.54 | 0.28 | 102.45 |
Repurchase of Common Stock | -0.04 | -0.02 | -0.05 | -0.03 | - | - |
Other Financing Activities | -1.02 | -1.61 | -0.47 | -0.99 | -2.65 | - |
Financing Cash Flow | 46.13 | 56.52 | 36.66 | 26.52 | 96.24 | 102.45 |
Net Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Cash Flow | -4.77 | -1.1 | -35.37 | -128.5 | -39.24 | 19.85 |
Free Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -50.9 | -57.62 | -72.03 | -155.03 | -135.48 | -82.6 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Margin | -6860.38% | -8974.30% | -3178.60% | -11233.77% | -36128.00% | - |
Free Cash Flow Per Share | -2.26 | -4.72 | -28.41 | -85.13 | -77.38 | -50.11 |
Levered Free Cash Flow | -31.75 | -39.35 | -48.68 | -96.21 | -75.59 | -42.62 |
Unlevered Free Cash Flow | -23.17 | -30.38 | -39.69 | -89.26 | -71.32 | -42.6 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash Interest Paid | 13.34 | 9.69 | 7.97 | 7.55 | 2.7 | 0.04 |
Change in Working Capital | 8.25 | 4.06 | 0.82 | 4.18 | 11.48 | 4.98 |